Autoimmune Diseases / 2017 / Article / Tab 4

Research Article

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

Table 4

The percent of PLN patients with MPO-ANCA absolute change and rate of rise over time above specific thresholds compared to matching healthy and SLE without LN disease controls. Only 20 cases and healthy controls and 19 SLE without LN disease controls had multiple samples to evaluate change over time. due to actual infinite value.
(a)

Change in MPO-ANCA
(U/mL/year)
Cases
(%)
Healthy controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

>0 U/mL70 (14/20)10 (2/20)213.7–120<0.001
>0.3 U/mL60 (12/20)0 (0/20)3.6–<0.001
>0.5 U/mL45 (9/20)0 (0/20)2.1–0.001
>1 U/mL20 (4/20)0 (0/20)0.7–0.10

(b)

Absolute rise in MPO-ANCA
(U/mL)
Cases
(%)
Healthy controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

>0 U/mL70 (14/20)10 (2/20)213.7–120<0.001
>1 U/mL55 (11/20)0 (0/20)3.0–<0.001
>2 U/mL35 (7/20)0 (0/20)1.4–0.008
>3 U/mL30 (6/20)0 (0/20)1.1–0.02

(c)

Change in MPO-ANCA
(U/mL/year)
Cases
(%)
Disease controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

>0 U/mL70 (14/20)16 (3/19)122.6–590.001
>0.3 U/mL60 (12/20)5 (1/19)273.0–49<0.001
>0.5 U/mL45 (9/20)0 (0/19)2.2–1790.001
>1 U/mL20 (4/20)0 (0/19)0.5–490.10

(d)

Absolute rise in MPO-ANCA
(U/mL)
Cases
(%)
Disease controls
(%)
OR
(odds ratio)
CI
(confidence interval)
value
(Fisher’s exact)

>0 U/mL70 (14/20)16 (3/19)122.6–590.001
>1 U/mL55 (11/20)11 (2/19)101.9–570.006
>2 U/mL35 (7/20)5 (1/19)101.1–890.04
>3 U/mL30 (6/20)0 (0/30)1.1–0.02

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.